Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Decreased by Fmr LLC

Fmr LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,199,579 shares of the biopharmaceutical company’s stock after selling 2,163,122 shares during the period. Fmr LLC owned about 7.46% of Regeneron Pharmaceuticals worth $5,840,807,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $28,000. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bernstein Bank decreased their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Stock Down 6.1 %

Regeneron Pharmaceuticals stock opened at $573.45 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $572.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $62.69 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 2.34 and a beta of 0.44. The company’s 50 day simple moving average is $676.70 and its 200 day simple moving average is $779.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.